{"meshTags":["Combined Modality Therapy","Female","Humans","Immunotherapy","Uterine Cervical Neoplasms"],"meshMinor":["Combined Modality Therapy","Female","Humans","Immunotherapy","Uterine Cervical Neoplasms"],"organisms":["9606","9606"],"publicationTypes":["Journal Article","Research Support, Non-U.S. Gov\u0027t","Review"],"abstract":"Cervical cancer is the third most common carcinoma in women worldwide. Despite increasing efforts to improve therapy in this disease, a significant proportion of women still die, mostly from recurrent or chemoresistant disease. This review discusses current treatments for early cervical cancer, advanced disease, and recurrent cervical cancer, and covers concurrent chemoradiation, neoadjuvant chemotherapy before surgery and radiation, single agent treatment, combination treatment, platinum-based and non-platinum based therapy. We also discuss promising therapeutics trategies for cervical cancer including targeted therapy, cell-based therapy, combined siRNA and chemotherapy, and immunotherapy.","title":"Current and potential treatments for cervical cancer.","pubmedId":"23259831"}